Hartmann Young’s Post

𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀: #𝗚𝗹𝗼𝗯𝗮𝗹 #𝗥𝗮𝗽𝗶𝗱 #𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗹𝗼𝗴𝘆 #𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗮𝗻𝗱 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 (𝟮𝟬𝟮𝟯-𝟮𝟬𝟮𝟵) Understanding Rapid Microbiology Testing Market Dynamics The market's vitality lies in its diverse applications across healthcare, food safety, pharmaceuticals, environmental monitoring, and more. Rapid microbiology testing facilitates quicker and more accurate microbial screening, crucial for disease diagnosis, product safety, and environmental monitoring. Key drivers propelling market growth include increasing healthcare expenditure, technological advancements, and rising awareness regarding infectious diseases. Global Reach and Regional Insights North America dominates the market, fueled by substantial investments in R&D and a proactive approach to disease detection. Europe is poised for significant growth, driven by advancements in microbiological testing and regulatory support. Emerging economies like India, South Korea, Brazil, and Mexico offer substantial growth opportunities, supported by improving healthcare infrastructure and rising disease prevalence. Navigating Challenges and Seizing Opportunities While the market presents immense growth potential, challenges such as high capital expenditure and operational barriers need to be addressed. Innovations in rapid testing methodologies, strategic partnerships, and regulatory compliance will be pivotal in overcoming these challenges and fostering market growth. 𝗗𝗼𝗻'𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝘁 𝗼𝗻 𝘁𝗵𝗶𝘀 𝗥𝗮𝗽𝗶𝗱 𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁—𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗽𝗼𝗿𝘁 𝘁𝗼𝗱𝗮𝘆! https://lnkd.in/dNRMMU7t #RapidMicrobiologyTesting #MicrobiologyMarket #BiotechIndustry #MedicalDevices #HealthcareInnovation #InfectiousDiseaseDetection #HealthTech #MedicalTechnology

New Investor Member: The Riverside Company is a global private investment firm focused on driving growth for companies at the smaller end of the middle market in Europe, North America and Australia. With approximately $13 billion in assets under management, Riverside has completed more than 1,000 investments since its founding in 1988. Healthcare investing is one of Riverside’s most active specializations, with more than 200 deals completed in the space. The firm’s current portfolio, inclusive of add-ons, features more than 65 healthcare company investments.    In Europe, the latest Riverside Europe Fund targets control buyouts of companies with up to €30 million EBITDA. Current European healthcare investments include: + A.forall (Global specialty pharma group which develops value-added generic pharmaceuticals, solve product shortages and fill unmet medical needs so that patients can continue their treatment) + BioDue spa (Italian CDMO focused on the research, development, production and commercialization of cosmetic products, medical devices and food supplements, both liquid and solid) + Dastex Reinraumzubehör GmbH & Co. KG (European leader in contamination control for cleanrooms) + HTBA (HealthTech BioActives) (Global leader in natural flavonoids and B12 derivatives, producing solutions for Pharmaceutical APIs, Taste Modulation, Health Functional, and Animal Nutrition, from naturally sourced materials) Visit https://lnkd.in/d_f39Z_N to learn more about Riverside's Healthcare specialization.    Damien Gaudin, Jeroen Lenssen, Tommy Seddon, Dan Parksjö, Maxime Meulemeester, Laura de Palacio Aragón, Nicola Philipp Tomaschko, Bence Putnoky,Jaime García-Oliveros Serrano, Filip Van de Vliet   #privateequity #investing #healthcare #lifesciences #medtech #pharma #naturalingredients #healthcaretechnology #foodsupplements #CDMO #CRO #GMP #API 

Can policies for incentivizing market entry of other products be applied to novel antibiotics and diagnostics to address #AntimicrobialResistance? Sabine Vogler et al. investigate in their new paper just published in AHEHP, which includes a nice graphical abstract 😃 #AMR #PullIncentives https://lnkd.in/gF2Tb_Rd (link to free-to-read version in comments)

The global microbial identification market has been thriving, and it's only getting bigger and better! 💼💸 • Revenue in 2020: $3.2 billion 💰 • Projected value by 2025: $5.7 billion 💵 • Impressive CAGR from 2020 to 2025: 12.2% 📊 Download PDF Brochure-https://lnkd.in/dfxBFZKY North America accounted for the largest share of the microbial identification market in 2019. In 2019, North America accounted for the largest share of the overall market, followed by Europe. Technological advancements in microbial identification, increasing prevalence of infectious diseases, growing food safety concerns, and the presence of prominent players are the major drivers of the North American market. The microbial identification market is dominated by a few globally established players such as bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Bruker Corporation (US), Shimadzu Corporation (Japan), QIAGEN NV (Netherlands), Avantor, Inc. (US), and Biolog, Inc. (US) #HealthcareInnovation #MicrobialIdentification #GlobalHealth #ScienceandTechnology #MarketTrends #HealthcareIndustry #FutureofHealthcare #DiseasePrevention #Biotechnology #MedicalAdvancements #InfectiousDiseases #HealthcareLeaders #ResearchandDevelopment #PublicHealth #HealthcareProfessionals #HealthcareNews

In 2019 alone, 1.27 million people died of drug-resistant infections, disproportionately affecting people in #LMICs. To minimise the spread of #AMR and save lives, #pharma companies need to scale up their efforts to ensure widespread access to effective #antibiotics, and they need to do so responsibly. Read the op-ed to learn what steps they can take to drive meaningful change across the supply chain.

From topical drug administration to agricultural spray applications, aerosol technology is proving to be incredibly versatile across applications. Moreover, these devices' ability to precisely control how products are administered is introducing innovative solutions for diverse non-respiratory needs, as well. Accordingly, our latest blog ‘Aerosol Delivery Devices Market: Non-Respiratory Applications,’ explores three such industries where aerosol-based devices are gaining broader acknowledgment. Check here: https://lnkd.in/dnKXTrK7 So, take a look and like & follow us for more! As industries witness the tangible benefits of aerosol technology, do you think there are more untapped sectors or applications where it could bring about significant innovations and improvements? Share your thoughts in the comments below! . . . Aerogen Gerresheimer Iconovo AB MERXIN Ltd #aerosoldeliverydevices #aerosol #healthcare #medicaldevices #marketanalysis #inkwoodresearch

No other sector is as diverse as the healthcare sector, and no other sector is subject to the same degree of constant change. With factors like an aging population, advancing technology, and growing demands, healthcare costs are rising.   For years, Rebels have played a crucial role in supporting the healthcare industry. We specialize in crafting and implementing innovative solutions that align with our beliefs. Our unique blend of financial expertise and in-depth sector knowledge enables us to offer top-tier advice for the healthcare sector.   Some of our notable healthcare projects include: 𝗦𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗿𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗶𝗻 𝗕𝗼𝘁𝘀𝘄𝗮𝗻𝗮 In Botswana, our Rebels Andreas Bertoldi and Barend van Lieshout supported local pharmaceutical production through a feasibility study considering the region's specific disease burdens. Discover more: https://lnkd.in/gazb-pKD 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗮𝗹𝗹-𝗲𝗹𝗲𝗰𝘁𝗿𝗶𝗰 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹 Our Rebels—Edwin Gulickx, Sierd Bron, and Kees Hörchner—contributed to securing funding for the Netherlands' first fully electric hospital, which opened its doors in Meppel in June 2022. Learn more: https://lnkd.in/gUSQ_bgz   Learn more about our healthcare expertise here: https://lnkd.in/g3qmCqPt   #healthcare #recycling #circular #sustainability

🌟 Unlocking the Potential of Animal Blood Plasma Products and Derivatives Market! 🌟 We're excited to share our latest research report on the Animal Blood Plasma Products and Derivatives Market—projected to grow at a CAGR of 3.5% and reach USD 2.21 billion by 2029! 📈 Sample Report Link :https://lnkd.in/g_srEmWx 🔬 Key Highlights: Market Growth: Driven by high-quality slaughter animal blood, rich in proteins and nutritional value. Applications: Dominating sectors include Cell Culture Media and the Food Industry, with significant contributions from Pharmaceuticals, Sports Nutrition, and Cosmetics. Regional Insights: North America leads the market, contributing over 35% share in 2022, with strong growth prospects in APAC, Europe, MEA, and Latin America. Strategic Moves: Leading companies like Lake Immunogenics, Auckland Biosciences, and Sigma-Aldrich are expanding through mergers, acquisitions, and partnerships in emerging markets. Key Players 1. Lake Immunogenics 2. Auckland Biosciences 3. Kraeber & Co. 4. GmbH 5. Sigma-Aldrich #AnimalBloodPlasma #Spurs #Tottenham #TOTMCI #Biotechnology #NutritionalSupplements #Pharmaceuticals #FoodIndustry

AMR isn’t only the consequence of antibiotic usage in healthcare, but is also caused by the "uncontrolled use of antibiotics in both the health and agriculture sectors"[1]. Due to the complex drivers of AMR, modeling the exact trajectory of antibiotic resistance and the minute alterations in antibiotic consumption remains a complex task [17, 18], and what is hard to measure, is hard to fix, especially when a global response is required. Visit the Senzo website to request the full report... #AMR #AntimicrobialResistance #Superbugs #PostAntibioticEra #AntibioticStewardship #InfectionControl #GlobalHealth #AMRActionFund #Diagnostics #NewAntibiotics #InfectiousDiseases #DrugResistance #Healthcare #PublicHealth #Medicine #Pharma #Biotech #IDWeek #ASMmicrobe #ICAAC #ECCMID #microbiology